ChemoCentryx (CCXI) Hits New 52-Week Low at $5.86

Shares of ChemoCentryx Inc (NASDAQ:CCXI) hit a new 52-week low during mid-day trading on Wednesday . The stock traded as low as $5.86 and last traded at $6.29, with a volume of 57400 shares traded. The stock had previously closed at $6.47.

Several analysts have issued reports on the company. Cowen reaffirmed a “hold” rating on shares of ChemoCentryx in a research note on Tuesday, August 8th. Zacks Investment Research lowered ChemoCentryx from a “buy” rating to a “sell” rating in a research note on Friday, August 11th. BidaskClub lowered ChemoCentryx from a “buy” rating to a “hold” rating in a research note on Friday, August 18th. Finally, ValuEngine downgraded ChemoCentryx from a “hold” rating to a “sell” rating in a research report on Saturday, October 21st. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and one has issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $8.25.

ChemoCentryx (NASDAQ:CCXI) last announced its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.13. sell-side analysts predict that ChemoCentryx Inc will post -0.67 earnings per share for the current year.

Institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. raised its holdings in shares of ChemoCentryx by 4.1% during the first quarter. Vanguard Group Inc. now owns 1,198,730 shares of the biopharmaceutical company’s stock valued at $8,727,000 after acquiring an additional 47,475 shares in the last quarter. Schwab Charles Investment Management Inc. raised its holdings in shares of ChemoCentryx by 80.6% during the second quarter. Schwab Charles Investment Management Inc. now owns 57,800 shares of the biopharmaceutical company’s stock valued at $542,000 after acquiring an additional 25,800 shares in the last quarter. BB&T Securities LLC bought a new position in shares of ChemoCentryx during the second quarter valued at approximately $781,000. Wedge Capital Management L L P NC bought a new position in shares of ChemoCentryx during the second quarter valued at approximately $424,000. Finally, Russell Investments Group Ltd. raised its holdings in shares of ChemoCentryx by 23.3% during the second quarter. Russell Investments Group Ltd. now owns 116,087 shares of the biopharmaceutical company’s stock valued at $1,087,000 after acquiring an additional 21,922 shares in the last quarter. Institutional investors own 48.89% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece of content was first reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark law. The correct version of this piece of content can be read at https://www.com-unik.info/2017/12/06/chemocentryx-ccxi-hits-new-52-week-low-at-5-86.html.

About ChemoCentryx

ChemoCentryx, Inc is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact.

What are top analysts saying about ChemoCentryx Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for ChemoCentryx Inc and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit